TY - JOUR T1 - Pilot Study on the Feasibility of PET/CT Lymphoscintigraphy with <sup>89</sup>Zr-Nanocolloidal Albumin for Sentinel Node Identification in Oral Cancer Patients JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 585 LP - 589 DO - 10.2967/jnumed.112.115188 VL - 54 IS - 4 AU - Derrek A. Heuveling AU - Annelies van Schie AU - Danielle J. Vugts AU - N. Harry Hendrikse AU - Maqsood Yaqub AU - Otto S. Hoekstra AU - K. Hakki Karagozoglu AU - C. René Leemans AU - Guus A.M.S. van Dongen AU - Remco de Bree Y1 - 2013/04/01 UR - http://jnm.snmjournals.org/content/54/4/585.abstract N2 - With conventional imaging techniques such as planar lymphoscintigraphy and SPECT/CT, preoperative sentinel node (SN) identification can be difficult when the SN is near the primary tumor, as is the case in floor-of-mouth carcinomas. PET/CT lymphoscintigraphy may improve the detection and localization of such SNs. Methods: In this study, the clinical feasibility of PET/CT lymphoscintigraphy using 89Zr-nanocolloidal albumin was evaluated in 5 oral cancer patients. PET/CT lymphoscintigraphy was performed after peritumoral injection of 89Zr-nanocolloidal albumin. The routine SN procedure, including SPECT/CT using 99mTc-nanocolloidal albumin, was performed on the same patients 7–9 d after the injection of 89Zr-nanocolloidal albumin. Results: Comparison of radiocolloid distribution on PET/CT and SPECT/CT showed identical drainage patterns. Moreover, PET/CT was able to identify additional foci near the primary tumor. Conclusion: This pilot PET/CT study on SN detection indicated that lymphoscintigraphy using 89Zr-nanocolloidal albumin is feasible. ER -